Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18133469 | 0.81 | TP53 (0.41) | HSD11B1 | |
| SCHEMBL20009002 | 0.81 | TP53 (0.41) | HSD11B1 | |
| SCHEMBL20009061 | 0.81 | TP53 (0.41) | HSD11B1 | |
| SCHEMBL20111634 | 0.79 | SMYD3 (0.31) | SMYD3 | |
| SCHEMBL20008953 | 0.79 | KDM4E (0.35) | HSD11B1SMYD3 | |
| SCHEMBL20111909 | 0.76 | SMYD3 (0.30) | SMYD3 | |
| SCHEMBL20111629 | 0.72 | PIK3CA (0.32) | SMYD3 | |
| SCHEMBL21732717 | 0.72 | HSD11B1 (0.32) | HSD11B1 | |
| SCHEMBL20012899 | 0.71 | THRB (0.33) | HSD11B1SMYD3 | |
| SCHEMBL20009018 | 0.71 | SMYD3 (0.39) | HSD11B1SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | HSD11B1 2021/4885SMYD3 1086/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | HSD11B1 2021/4885SMYD3 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.